With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a placebo-controlled trial involving men with non-metastatic HSPC. Denosumab ...

Despite the efficacious role of IV bisphosphonate treatment in MM, few studies have described their real-world utilization patterns among older patients and minority groups, patient populations ...

On the basis of our studies, we estimated that bisphosphonate treatment would result in an annual rate of 2.3 subtrochanteric or diaphyseal fractures per 10,000 patient-years in untreated women ...

A recent case-control study showed an inverse association between bisphosphonate use and colorectal cancer. Data from prospective cohorts are lacking. Patients and Methods. We prospectively examined ...

Bisphosphonate-mediated inhibition of osteoclast function seems to decrease bone resorption and inhibit normal bone turnover remodelling. Bone resorption and remodelling play an essential role in ...

Each bisphosphonate registration trial enrolled 3000 to 7500 patients and was powered for the demonstration of fracture efficacy, whereas the long-term extension studies, ...

Bisphosphonate associated osteonecrosis of the jaws (BONJ) has been well documented recently in relation to intravenous preparations of the drug. These are most commonly used as part of the ...

Bisphosphonate use is associated with an increased risk of developing atypical femur fractures, but the incidence is still low. News & Perspective Drugs & Diseases ...

In the CPRD cohort, researchers observed 5,234 deaths among bisphosphonate users (27%) during 45,690 person-years of follow-up, and 85,105 deaths among nonusers (40%) during 915,867 person-years ...

Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial.

U.S. regulators said on Wednesday they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc's <MRK.N> Fosamax and certain thigh bone fractures. ><BR> The ...

With the risk of ONJ for oral bisphosphonate users apparently falling somewhere in the 1 in 100,000 patient-treatment-years range, the risk-benefit analysis is an easy one, Shane said.